Pfizer’s recent Phase 3 success with BRAFTOVI in combination regimens and the expanded label for PADCEV plus Keytruda have positioned the company for blockbuster growth in precision oncology. In late 2025, the BRAFTOVI Phase 3 trial in BRAFV600E-mutant colorectal cancer met its primary endpoint, demonstrating a statistically significant improvement in median progression-free survival by 5.4 months versus standard of care. Meanwhile, the U.S. Food and Drug Administration’s decision to broaden PADCEV plus Keytruda to include second-line urothelial carcinoma is expected to add approximately 25,000 new eligible patients annually in North America and Europe. Together, these milestones underpin management’s forecast of low-double-digit percentage oncology revenue growth through 2028.

Pfizer’s revitalized obesity franchise, anchored by the injectable GLP-1 candidate MET-097i and an undisclosed oral small molecule, could catalyze a re-rating if Phase 3 trials read out positively in mid-2027. MET-097i’s global registrational program enrolled over 2,000 patients across three pivotal studies, each designed to demonstrate at least 15% mean weight reduction at 52 weeks versus placebo. The oral candidate, expected to enter Phase 2 next quarter, employs a dual-agonist mechanism targeting GLP-1 and GIP receptors. Analysts project peak obesity franchise sales of $8–10 billion annually by 2030, based on conservative market-share assumptions.

In 2025, Pfizer initiated a company-wide restructuring program targeting $1.8 billion in annual cost savings by the end of 2026. Key actions include the consolidation of three global R&D sites into two centers of excellence and a 12% reduction in global commercial headcount. As of Q4, management reported realization of $1.1 billion in run-rate savings, contributing to a free cash flow margin of 25%. These efficiencies are expected to fund incremental investments in high-growth programs while maintaining a dividend yield above 4%.

Despite recent share price volatility, Pfizer trades at a low-twenties forward P/E ratio, representing a 15% discount to the broader pharmaceutical sector average. The stock’s free cash flow yield of roughly 5% is among the highest in the peer group, underpinning the ‘Strong Buy’ consensus rating among eight analysts surveyed. With a reported net debt-to-EBITDA ratio of 1.9x and planned share repurchases of $10 billion over the next two years, the company’s balance sheet remains robust. Looking ahead, catalysts include BRAFTOVI label expansions, MET-097i Phase 3 readouts, and continued margin improvement, all of which could drive total shareholder returns of 12–15% annually through 2028.